HomeTrialNCT06719011
🔬NCT06719011Phase 1RECRUITING

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Study Summary

This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine. Participants will either get the new study medicine NNC0174-1213, a study medicine called "cagrilintide" or a placebo (a "dummy medicine" similar to the new study medicine and study medicine but without active ingredients). Which treatment participants will get is decided by chance. The new study medicine and the study medicine are potential new medicines which cannot be prescribed by doctors. This study will last for about a year in total.

View on ClinicalTrials.gov ↗
Study Details
Enrollment177 participants
Primary Completion
Lead SponsorNovo Nordisk A/S
Data Retrieved2026-04-11 02:55:47.366473+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.